Recent Updates
Recently added Catalysts
DARE Positive Sentiment

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Key Takeaway: Daré Bioscience, a biotech company dedicated to women's health, announced its participation in the virtual investor series titled 'Why Now'. The company aims to bridge the gap between scientific advancements and practical solutions for women's health. A video webcast of the event is now available for interested viewers.
Price reaction · baseline $0.7506 (2026-08-26 close) · hit pre-market · clean, no other DARE news in the window
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Daré Bioscience is focused on women's health solutions.
  • Participation in the investor series highlights company engagement.
  • The webcast is now available for broader audience access.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8.6%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
DARE-HPV
Phase 2 · Human Papilloma Virus (HPV)

Full Press Release Details

Video webcast now available here
SAN DIEGO , Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in the Virtual Investor “Why Now” on-demand series .
For the webcast, Sabrina Martucci Johnson , President and Chief Executive Officer of Daré Bioscience, presented the Company's investment thesis, highlighting its mission to advance innovative solutions that address significant unmet needs in women's health through a differentiated, science based and capital-efficient business model. Ms. Johnson underscored Daré Bioscience's first direct product launch, its diversified pipeline, and its strategic collaboration-driven development approach.
The video webcast is now accessible for on-demand viewing here .
ABOUT DARÉ BIOSCIENCE, INC.
Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com .

Frequently Asked Questions

What is the focus of Daré Bioscience?

Daré Bioscience focuses on closing the gap in women's health through innovative solutions.

Where can I watch the investor series webcast?

The video webcast of the investor series is available online.

Who is the CEO of Daré Bioscience?

The CEO of Daré Bioscience is Sabrina Martucci Johnson.

What was the event Daré Bioscience participated in?

Daré Bioscience participated in the virtual investor series titled 'Why Now'.

Last updated: Aug 27, 2026